Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | EDNRB | P24530 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6042649 | 0.85 | ALDH1A1 (0.45) | KDM4EMAPTALDH1A1 | |
| SCHEMBL20989275 | 0.84 | RAB9A (0.39) | EPHX2NPC1RAB9ALMNAKDM4E | |
| SCHEMBL20988745 | 0.76 | SCD5 (0.38) | ALDH1A1 | |
| SCHEMBL20989056 | 0.76 | CYP2C19 (0.47) | ALDH1A1 | |
| SCHEMBL6958385 | 0.75 | MAPT (0.41) | KDM4EMAPTALDH1A1 | |
| SCHEMBL20989118 | 0.73 | POLB (0.40) | NPC1RAB9AMAPTEDNRBALDH1A1 | |
| SCHEMBL3415324 | 0.73 | NPC1 (0.47) | NPC1RAB9AMAPT | |
| SCHEMBL20989281 | 0.73 | OXTR (0.47) | LMNAALDH1A1 | |
| SCHEMBL20988802 | 0.73 | ALDH1A1 (0.46) | LMNAALDH1A1 | |
| SCHEMBL6954030 | 0.73 | MAPT (0.39) | NPC1RAB9ALMNAKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11344559-B2 | PI3KGAMMA inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-05-31 | — | — | US | disclosed |
| US-11344559-B2 | PI3KGAMMA inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-05-31 | — | — | US | disclosed |
| US-20200405730-A1 | PI3KGAMMA INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-12-31 | — | — | US | disclosed |
| US-20200405730-A1 | PI3KGAMMA INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-12-31 | — | — | US | disclosed |
| WO-2020264120-A1 | PI3KGAMMA INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200405730-A1 | PI3KGAMMA INHIBITORS | PIK3R5, PI4KB, PIK3R4 | EPHX2 3901/4885NPC1 3286/4885RAB9A 772/4885 |
| US-11344559-B2 | PI3KGAMMA inhibitors | PIK3R5, PI4KB, PIK3R4 | EPHX2 3901/4885NPC1 3286/4885RAB9A 772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.